Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel)
Information source: University of Basel
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Opioid Dependence
Intervention: Cortisol 20 mg (Drug); Mannitol (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Prof. Dominique de Quervain, MD
Summary
To investigate the effects of cortisol on heroin craving and stress reaction in heroin
addicted subjects Randomized, double-blind, placebo-controlled, cross-over, single
administration of study medication Study hypothesis: Cortisol has an inhibiting effect on
heroin craving and stress reactivity in opioid dependent subjects.
Clinical Details
Official title: Acute Effects of Cortisol on Heroin Craving in Opioid Dependence
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Heroin craving
Secondary outcome: Anxiety
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age ≥ 18
- Opioid dependency
- Participant in the Janus heroin programme of the UPK Basel
- Able to control parallel consumption of other drugs
- Stable i. v. substitution for at least 3 months
Exclusion Criteria:
- co-morbid psychiatric disturbances
- Current medical conditions excluding participation
- Recent history of systemic or topic glucocorticoid therapy
- known hypersensitivity to the IMP under investigation (cor-tisol)
- pregnancy, breast-feeding
- inability to read and understand the participant's information
Locations and Contacts
Psychiatric Hospital, Basel 4012, Switzerland
Additional Information
Starting date: November 2012
Last updated: October 29, 2013
|
